ANN ARBOR, Mich., February 1, 2023 (Newswire.com) - GreenMark Biomedical Inc. "GreenMark" announces its award in the competitive Startup Central Pitch event called The Hub, which the company received on Friday, Jan. 27, 2023 in Boston, Massachusetts. GreenMark's CEO Dr. Steven Bloembergen took part in the event, along with six other CEOs of dental startup ventures with a presentation entitled "Redefining Caries Management: Transforming the dental experience through early detection and noninvasive treatment". 

GreenMark captured the winning "Best Startup", with eligibility for a $50,000 investment award. The event, organized by Revere Partners, was judged by professionals with a broad range of expertise in the dental market, and consisted of an oral presentation on innovative products by each company, followed by questions from the judges. After winning, Bloembergen stated, "We are thrilled to have been selected first in this competitive event with other innovation companies. This event allowed us to showcase our system approach to redefining caries management with our novel LumiCare™, LumiKids™ and planned CrystLCare™ products."

Startup Central included GreenMark among ten company participants, and was dedicated to disruptive innovations in dentistry, as part of a three-day exhibit at the Yankee Dental Congress. This meeting was held at the Boston Convention and Exhibition Center on Jan. 26-28, 2023. The Startup Central exhibit and The Hub competitive startup event were sponsored by Revere Partners, the first independent Venture Capital fund exclusively dedicated to oral health. The VC fund identifies opportunities for investors, providing capital for cutting-edge innovations in the oral and oral/systemic health sectors.

"Revere selected the winner based on key factors contributing to startup growth in dentistry, such as: team, marketing opportunity, product, clarity of the presentation, equity and accessibility to patients, and the likelihood of successfully closing their fundraising round," said Dr. Jeremy Krell, Managing Partner for Revere Partners, a general dentist and experienced investor. 

"Receiving this award is especially meaningful for us at GreenMark, as we are in the midst of raising our Series A investment round," said Steven Bloembergen, Ph.D., GreenMark's founder, Chairman and CEO. He added, "Since 2016, we've invested in our bioresorbable starch particle platform, to bring affordable, safe and effective products to the dental market, with the goal of improving oral health for all." 

About GreenMark Biomedical Inc. 

GreenMark is developing a systems-based approach to caries management, with its patented products that involve small sub-micron particles, produced from safe food-grade starch. These make an ideal carrier for medical and dental applications, since enzymes in the human body and saliva degrade starch. Dental caries (tooth decay) is the most prevalent chronic disease in the world, affecting more than 95% of Americans over their lifetimes. Minerals are gradually lost from affected tooth surfaces, and enamel becomes increasingly porous, until eventually a cavity forms. GreenMark is developing methods to identify and better assess the disease in its early stages, monitor progression and to manage it, noninvasively and without anesthesia. The company's "LumiCare™ Caries Detection Rinse" and half-dose "LumiKids™ Caries Detection Rinse" products, to be used by dental professionals as part of the routine dental exam, contain fluorescent-labeled starch particles that target the porous subsurface of caries lesions in enamel, and illuminate them using a dental curing light, thereby aiding in the visualization of caries. The identification at early stages before a cavity forms allows the use of preventive, non-surgical management options, resulting in less discomfort and improved long-term oral health outcomes for patients. GreenMark's team has also demonstrated the ability to load the essential enamel minerals, depleted because of tooth decay, inside the small starch particles, and is now developing treatment products designed to target and restore minerals to the subsurface of teeth. The company intends to launch its "CrystLCare™ Biorestorative, Fluoride-Free" product soon, an Easy-to-Use Dissolvable Dental Strip, packaged in convenient single-use sleeves, for the prevention and control of dental hypersensitivity. After release of its mineral components, the product works by forming hydroxyapatite crystals to block exposed dentin. Contact [email protected], or call 801-899-0710. For more information, visit www.greenmark.bio. 

About Revere Partners 

Revere Partners is the first venture capital fund exclusively focused on oral health, identifying opportunities for investors and providing capital for cutting-edge innovations in the oral and oral/systemic health sectors. Revere Partners' inaugural fund has a flexible and unique structure with continuously open fundraising that enables startups to connect with unrivaled industry resources and growth opportunities. Founded by Dr. Jeremy Krell and David Arena, Revere Partners fosters strategic partnerships that improve care delivery as well as patient and provider experiences - maximizing value for investors. Revere Partners is committed to inclusive partnerships with underserved businesses in the healthcare sector, including but not limited to, women, minority and LBGTQ+-owned enterprises. To learn more visit www.reverepartnersvc.com or on LinkedIn.

Contact Information:
Steven Bloembergen
Ph.D.
[email protected]
‭(517) 896-3665‬
Related Images


Original Source: GreenMark Biomedical Wins Competitive Startup Pitch Event at 2023 Yankee Dental Meeting

1nHealth presented 941 total patients with opportunities to join relevant online communities with The Mighty

ORLANDO, Fla., February 1, 2023 (Newswire.com) - Clinical trials bring hope to patients by exposing them to potentially groundbreaking therapies. Thus, it can be especially devastating for patients to learn about a clinical trial and then fail to qualify for participation.  

1nHealth and The Mighty have teamed up to route patients who may not qualify for a specific trial to condition-focused communities on The Mighty where those patients can get support, read stories that provide representation, and be part of a community of those with similar health journeys. Patient Centricity means keeping the focus on people, and this partnership enables that to extend all the way to the recruitment stage. 

"Teaming up with 1nHealth is such a great opportunity," says President of The Mighty Matthew Michelson, Ph.D. "The Mighty is here for patients in need, especially when the chips are down. And when patients hear about potential live-changing therapies and then can't participate, that's a blow. Now, at that exact point, they'll be directed to communities on The Mighty that identify with their struggle — and that deep representation and community is powerful." 

The process begins when a patient clicks on a 1nHealth study advertisement for a specific clinical trial. On 1nHealth's study screener, a patient submits their information. If a patient fails to meet the inclusion criteria for the trial, they are presented with opportunities to engage with communities of relevance on The Mighty. Patients can then join those communities and be part of the conversation. 

"We often see support for patient centricity in a performative way," says 1nHealth CEO Dan Brenner. "At 1nHealth, we want to serve all patients, not just the patients who qualify for a study. Those who submit their information in prescreening are clearly looking for help, and we want to be a resource for them even if that specific trial cannot be the solution. This partnership with The Mighty furthers our mission to put patients first." 

To date, the partnership combined on multiple studies, presenting 941 patients the opportunity to join relevant communities on The Mighty. 1nHealth and The Mighty will continue to implement this offering for clients who opt in.  

Contact Information:
Albany Alexander
Growth Manager at 1nHealth
[email protected]
4076004693

Matt Michelson
President of The Mighty
[email protected]


Original Source: 1nHealth Partners With The Mighty to Bring Fresh Patient Centricity to Clinical Trial Recruitment

The Spire Health Pathways clinic located in Denver, Colorado, is taking a fresh approach to Functional Medicine by contracting with government and commercial insurance to bring the healing powers of functional medicine to all Coloradans and for a fraction of the typical price.

DENVER, February 1, 2023 (Newswire.com) - A Functional Medicine practice with a fresh approach opens in southeast Denver. Located at 6895 E. Hampden Ave., Unit B, Denver, CO 80224, the Spire Health Pathways clinic, led by Dr. Crystal Dickerson, MD, opened its doors this year. The clinic is located in the building with AfterOurs Urgent Care just east of I-25. Spire Health Pathways is dedicated to providing comprehensive and personalized health and wellness services to clients through advances in Functional Medicine.  

Functional medicine is a holistic approach to healthcare that focuses on identifying and treating the root causes of disease, rather than just managing symptoms. It involves a detailed analysis of a patient's medical history, lifestyle, and environmental factors to determine what evaluations are necessary including advanced and specialty testing to create a personalized treatment plan. Practitioners of functional medicine may use a combination of conventional and alternative therapies, such as nutrition, supplements, and acupuncture, to address imbalances in the body and support optimal health. Spire Health Pathways will soon be adding optional Wellness Coaching and IV Therapies to the suite of services. With these new services, patients can achieve accelerated positive outcomes on their health journey. The goal of functional medicine is to not only alleviate symptoms but to also promote overall wellness and prevent future illness by addressing the underlying causes.

Spire Health Pathways is committed to creating an inclusive and welcoming environment for all community members. Spire's services are tailored to meet the unique needs of each individual, and they work closely with the clients to set and achieve health and wellness goals. Dr. Dickerson commented on how this practice differs from almost any in Colorado: "Functional Medicine is gaining tremendous adoption across the country, but functional medicine practices often avoid contracting with insurance. This makes the solution cost prohibitive for value-minded patients." 

Many people find it difficult to pay for services outside of their insurance company provider network. The team has secured in-network contracts with Aetna, Medicare, Colorado Medicaid, BCBS, and contracts with the other major Colorado payors are in process. Though it complicates the business, it conveys the concern for the patient's well-being, including financial well-being. Dr. Dickerson concludes: "We want to touch as many people in our community as possible … We want to guide them on the path to feeling their best!" 

For more information about Spire Health Pathways, visit their website, call them at (720) 575-1922, or send them an email to [email protected].

Contact Information:
Crystal Dickerson
Physician / Medical Director
[email protected]
(720) 575-1922

Dan McDermott
Executive Director
[email protected]
(720) 318-8791


Original Source: Spire Health Pathways - Functional Medicine Practice is Open for Business in Denver, Colorado

ALBANY, N.Y., February 1, 2023 (Newswire.com) - Fort Orange Press is pleased to announce the hire of Bryan Dandurand as Senior Vice President of Operations. Bryan comes to Fort Orange Press from Runbeck Election Services, bringing over 30 years of experience in print manufacturing. Over the past 10 years, Bryan has continued to be at the forefront of operational excellence, having pioneered the process and procedures of vote-by-mail ballot production.

Since 1905, Fort Orange Press has successfully printed election ballots in New York State. Today, Fort Orange Press continues to lead the way in ballot printing by delivering top talent resources, streamlined processes and exemplary technology in the ever-growing vote-by-mail arena. The footprint of Fort Orange Press continues to grow throughout the United States, providing safe and secure vote-by-mail initiatives.

"I am excited to have Bryan join the Fort Orange Press team in this new role. Not only does Bryan bring 35 years of expertise in election ballot printing, he has significant experience in vote-by-mail printing, inserting and mailing. Bryan fully understands and has mastered the necessary disciplines and operational procedures to keep Fort Orange Press at the forefront of error-free vote-by-mail elections," says Robert Witko, President and CEO.

Personally, Bryan enjoys catching up on binge-worthy series with his beloved wife and dog. As new residents of the Northeast, they are excited to explore the region. Bryan is a devoted family man who enjoys spending quality time with his children and grandchildren. He is a strong chess player and has been known to challenge his coworkers to a game when the opportunity arises. "I am thrilled and honored to join Fort Orange Press. The company's 118-year proven track record and continued commitment to the future of ballot production is a winning combination. I look forward to bringing my skills to Fort Orange Press and contributing to the continued growth and future success of the company," says Dandurand.

ABOUT FORT ORANGE PRESS
Fort Orange Press fulfills clients' mission-critical printing and mailing needs from its high-tech, fully secure, modern facility in Albany, NY. Since 1905, Fort Orange Press has been a trusted partner to state and local municipalities and is one of the nation's leading ballot printing and mailing experts. Fort Orange Press' continued investment in leading-edge technology and process enhancements has provided an efficient, accurate and secure program for printing and mailing. Fort Orange Press' full services include data management and processing, intelligent printing, high-speed and secure inserting, fulfillment and mailing, as well as tracking and reporting technology to provide even further transparency for clients.

For more information, email [email protected] or go to www.fortorangepress.com/election.

Contact Information:
Kari Berman
Director of Human Resources
[email protected]
(518) 810-6267


Original Source: Fort Orange Press Names Bryan Dandurand to Senior Vice President of Operations

SAN DIEGO, February 1, 2023 (Newswire.com) - On Feb. 26, 2022, Rancho Biosciences, a leading data sciences services company, launched its Single Cell Data Science (SCDS) pre-competitive consortium, with four Charter Members: Bristol Myers Squibb, Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis and Vesalius Therapeutics. Today, Rancho Biosciences is pleased to announce the addition of BenevolentAI as the fifth Member of the SCDS consortium.

The mission of the consortium is to find a common industry standard around how single-cell datasets are created and formatted by a systematic effort to develop data models and ensure that public data are curated in a consistent way. Due to the undeniable impact of single cell transcriptomics technology on drug discovery, there continues to be an exponential growth in the use of single cell sequencing methods by pharmaceutical companies. The availability of ever-increasing amounts of single cell datasets in the public domain allows pharmaceutical companies to dramatically expand their universe of single cell experiments over those generated internally. Leveraging this vast public data lake by finding, downloading, and curating single cell data is highly laborious and time-consuming compared to the resources for collectively analyzing data by scientists to gain value for biomedical research. 

Using its deep curation expertise and know-how, Rancho has delivered 83 analysis ready datasets to date. Each dataset includes 79 curated columns of metadata, validated against a 4-entity data model built by Rancho for SCDS. Prioritized by Members, Rancho will continue to deliver an ongoing stream of harmonized single cell datasets to the consortium. Under this shared cost model, these can be delivered at much higher throughput than one single company could achieve and much more cost-effectively. New Members are welcome.

About Rancho

Founded in 2012, Rancho Biosciences is a privately held company offering services for data curation, management and analysis for companies engaged in pharmaceutical research and development. Its clients include top 20 pharma and biotech companies, research foundations, government labs and academic groups.

For more information about Rancho and SCDS consortium, contact:

Andy Hope, PhD           

[email protected]

Contact Information:
Andy Hope
Business Development
[email protected]
6302407809


Original Source: Rancho Biosciences Welcomes BenevolentAI as New Member to Its Single Cell Data Science Consortium